ESMA’s January 2025 Stablecoin Statement: Is It Legally Binding — And Is It Even Correct?

1. Introduction: The Statement That Divided the EU Crypto Legal Community

On 17 January 2025 — less than three weeks after MiCA became fully applicable for CASPs on 30 December 2024 — the European Securities and Markets Authority issued a public statement titled “Provision of certain crypto-asset services in relation to non-MiCA compliant ARTs and EMTs.” On the same day, the European Commission published a Questions and Answers document addressing the same subject matter.

Together, these two publications fired a starting gun on what has become the most contested interpretive dispute in MiCA’s still-young enforcement history. ESMA’s statement effectively directed EU-licensed trading platforms to stop making non-MiCA-compliant asset-referenced tokens and e-money tokens available for trading. The Commission’s Q&A reinforced this position, suggesting that own-initiative admissions to trading by exchanges constituted “seeking admission to trading” under Articles 16(1) and 48(1) of MiCA.

The immediate market reaction was fragmented. Some exchanges, most notably Bitpanda, delisted USDT. Others maintained listings. Legal teams across the EU began reaching opposite conclusions from the same regulatory text. Within days, a 98-page legal opinion commissioned by the Sky DAO and published by BCAS Legal made the case that both publications materially misread MiCA — that own-initiative listings were not prohibited by Titles III or IV, that the non-compliant characterisation was legally inaccurate, and that ESMA’s statement itself exceeded the proper interpretive limits of a public statement.

This article subjects both publications to rigorous legal scrutiny. The goal is not to advocate for any particular commercial outcome — whether exchanges should delist USDT or maintain listings is ultimately a board-level risk decision informed by legal advice. The goal is to set out, with precision, where the ESMA statement and Commission Q&A are legally sustainable, where they overreach, and what the correct statutory analysis actually supports.

For compliance officers building their MiCA frameworks, understanding the strength and limitations of ESMA’s position is not an academic exercise. It determines the risk weight you assign to the statement when making consequential decisions about your token listing catalogue.

For the foundational overview of MiCA’s stablecoin classification framework and the underlying legal debate, see ComplyFactor’s MiCA stablecoin listings analysis and CASP admission to trading obligations guide. This article focuses specifically on the ESMA statement’s legal validity and the six principal arguments against it.

2. What ESMA Actually Said — and What the Commission Added

Before critiquing the ESMA statement and Commission Q&A, it is important to characterise precisely what each publication actually says. Both documents have been summarised loosely in market commentary, and imprecise characterisation distorts the legal analysis.

ESMA’s public statement makes the following principal assertions, in substance:

First, ARTs and EMTs whose issuers are not authorised under MiCA are “non-MiCA compliant ARTs and EMTs.” This terminology — which treats non-authorisation as equivalent to non-compliance — is the first point of legal contestation, as discussed in Critique 1 below.

Second, CASPs operating trading platforms are expected to “stop making all non-MiCA compliant ARTs and EMTs available for trading.” This is the operational directive at the heart of the controversy. ESMA frames this not as a recommendation but as an expectation — language that sits between formal requirement and soft guidance.

Third, ESMA states that only CASPs providing services that “amount to an offer to the public or seeking admission to trading” are “generally expected to prioritise restricting such existing services when they facilitate the acquisition of non-MiCA compliant ARTs and EMTs.” This formulation is actually narrower than the headline messaging — it conditions the expectation on the CASP’s service amounting to an offer to the public, which is itself contested.

The Commission’s Q&A makes several additional points. It states that operators of trading platforms listing ARTs or EMTs without issuer authorisation are to be considered as persons “seeking admission to trading on the own initiative of the operator under Articles 16(1) or Article 48(1).” This is the Commission’s attempt to bridge the textual gap — characterising own-initiative admissions as falling within the Articles 16(1)/48(1) prohibition on seeking admission to trading.

The Q&A also confirms that other crypto-asset services — including exchange, reception and transmission of orders, and execution of orders — constitute an offer to the public of non-MiCA-compliant ARTs and EMTs only “if the relevant CASPs promote or advertise, as part of these services, an ART or EMT.” This promotional threshold is an important limiting principle within the Commission’s own analysis, and is addressed in Critique 6 below.

3. The Legal Character of ESMA Public Statements Under EU Law

Any rigorous assessment of the ESMA statement must begin with its legal character under EU law. This is not a procedural technicality — it is a fundamental question that determines how much weight the statement carries in any enforcement or judicial proceeding.

ESMA is an EU supervisory authority established under Regulation (EU) No 1095/2010. Its legally binding instruments are limited to: binding technical standards (both regulatory technical standards and implementing technical standards) adopted through the formal delegated/implementing act procedure; binding decisions addressed to specific supervised entities or NCAs in specified circumstances; and peer review findings and breach of Union law investigations that can compel NCA action through formal processes.

A public statement — the instrument ESMA used in January 2025 — is categorically not one of these binding instruments. It is a supervisory communication, equivalent in legal character to a supervisory expectation or a Q&A publication. It expresses ESMA’s interpretation of the applicable law and its supervisory expectations of market participants and NCAs, but it does not create new legal obligations, and it does not have the force of law.

The distinction matters enormously in practice. A binding technical standard adopted under MiCA carries the same legal weight as MiCA itself — it is part of the regulatory framework. A public statement is ESMA’s opinion about what the regulatory framework already requires. If ESMA’s opinion is incorrect — if the statement misreads MiCA’s text — then the statement is simply wrong, regardless of ESMA’s authority and institutional standing. Courts, NCAs, and supervised entities are entitled to disagree with it.

This does not mean the statement is without practical consequences. NCAs across the EU will typically treat ESMA supervisory communications with significant deference, and an NCA that departs from ESMA’s expressed position without good reason risks supervisory convergence proceedings. But the statement is not law, and its correctness as a matter of statutory interpretation is legitimately contestable — as the BCAS legal opinion demonstrates in considerable detail.

The Commission’s Q&A carries similar legal character. Q&A documents published by the Commission are informal guidance — they represent the Commission’s interpretation of legislation it has proposed and that Parliament and Council have adopted, and they carry real weight in practice. But they are not legislative instruments. Where they misread the text of an EU regulation, they can be challenged.

4. Why NCAs Are Not Bound by the ESMA Statement

The question of whether NCAs are bound by the ESMA statement has direct practical consequences for CASPs in different member states. The answer is nuanced but ultimately clear: NCAs are not legally bound by ESMA public statements, though they face strong institutional incentives to align with them.

Under the MiCA framework, NCAs are the primary supervisors of CASPs in their home member states. They are responsible for authorisation, ongoing supervision, and enforcement. ESMA’s role in relation to CASPs is primarily one of supervisory convergence — ensuring that NCAs across the EU apply MiCA consistently — rather than direct supervision of individual firms.

ESMA’s tools for compelling NCA action where it believes an NCA is departing from proper application of EU law include the breach of Union law procedure under Article 17 of the ESMA Regulation, and peer review processes. These are formal, procedurally heavy mechanisms that ESMA would be unlikely to deploy in response to an NCA that simply took a different interpretive position on the own-initiative listing question without any contrary enforcement action.

The practical consequence is that NCA responses to the ESMA statement have varied and will continue to vary across member states. An NCA that is persuaded by ESMA’s analysis — or that faces domestic political pressure to enforce against non-MiCA-compliant stablecoin listings — will apply supervisory pressure on CASPs in its jurisdiction to delist. An NCA that remains formally silent, or that informally signals a more permissive approach, creates a materially different risk environment for CASPs authorised in that jurisdiction.

This jurisdictional divergence is not a temporary anomaly — it is a predictable consequence of EU supervisory architecture in the early stages of a new regulatory framework’s implementation, before ESMA’s supervisory convergence tools have been applied to produce consistent NCA approaches. For CASPs, the practical implication is that their home member state NCA’s posture is the single most important variable in their listing risk assessment — more important than ESMA’s statement in isolation.

The discussions captured in the MiCA compliance community’s telegram channels and forums reflect exactly this dynamic. Practitioners in different jurisdictions are reaching different conclusions not because they are reading different law, but because their NCAs are signalling different enforcement intentions — and those signals carry more practical weight than the ESMA statement itself.

5. Critique 1 — The “Non-Compliant” Characterisation Is Legally Imprecise

The ESMA statement’s use of the term “non-MiCA compliant ARTs and EMTs” to describe tokens whose issuers have not obtained MiCA authorisation is the first and perhaps most fundamental legal imprecision in the publication.

MiCA’s Title IV imposes obligations on persons who make an offer to the public of an EMT in the Union or seek its admission to trading on a trading platform in the Union. Article 48(1) sets out these conditions clearly — including a second subparagraph allowing third parties to offer or seek admission to trading of an EMT upon the written consent of the issuer, subject to Articles 50 and 53. An issuer who does none of the triggering acts — who merely issues the token, without offering it to the public in the Union, seeking any EU listing, or consenting in writing to a third party doing so — does not fall within the scope of Title IV. They are not subject to the authorisation requirement, the whitepaper obligation, or any other Title IV provision. They are, in the most precise sense, simply outside MiCA’s regulatory perimeter for the purposes of those obligations.

Describing such an issuer as “non-MiCA compliant” is therefore a category error. Compliance implies being subject to obligations and failing to meet them. An entity that is not subject to MiCA’s Title IV obligations cannot be non-compliant with those obligations — it is simply outside their scope. Tether Limited, from the perspective of MiCA’s text alone, is not “non-compliant” unless and until it conducts an offer to the public of USDT in the Union or seeks its admission to trading — at which point it becomes subject to and in breach of Title IV. In the absence of those triggering acts, Tether is simply an extra-EU issuer of a USD-pegged stablecoin.

This is not a semantic quibble. The “non-compliant” framing carries implicit regulatory content that the statute does not support. It suggests that there is a positive obligation on all EMT issuers to obtain MiCA authorisation — which would give MiCA effective global applicability — and that CASPs listing tokens from non-authorised issuers are therefore facilitating non-compliance. The BCAS opinion correctly identifies this as an untenable reading: if all issuers fell within MiCA’s scope regardless of whether they offered to the public or sought listing in the Union, then MiCA would regulate every stablecoin issuer anywhere in the world — a result the legislature plainly did not intend and that EU law has no jurisdictional basis to support.

The Commission’s Q&A is aware of this tension and attempts to address it by focusing on the specific services provided by CASPs rather than the issuer’s authorisation status per se. But the ESMA statement’s headline framing — “non-MiCA compliant ARTs and EMTs” — imports a legal conclusion that the statutory text does not sustain.

6. Critique 2 — The Own-Initiative Listing Prohibition Has No Textual Basis in Titles III or IV

The core legal argument against the ESMA statement — and the one most extensively developed in the BCAS opinion — is that nothing in MiCA’s Titles III or IV prohibits a CASP from admitting an ART or EMT to trading on its own initiative, provided the CASP meets its Title V obligations.

The textual analysis begins with Article 5(2) of MiCA, which sits under Title II and addresses non-stablecoin crypto-assets. Article 5(2) states that when a crypto-asset is admitted to trading on the initiative of the operator of a trading platform and a whitepaper has not been published in the cases required by the Regulation, the operator shall comply with the requirements of Article 5(1). Recital 32 mirrors this, confirming that the operator of a trading platform is responsible for complying with Title II requirements where crypto-assets are admitted on its own initiative.

The legislature therefore demonstrably knew how to address own-initiative admissions to trading when it wanted to. It did so in explicit terms for Title II assets. It did not do so for Title III assets (ARTs) or Title IV assets (EMTs). Under the standard principles of statutory interpretation — particularly the Latin maxim ubi lex voluit dixit, ubi noluit tacuit, meaning where the law willed it, it spoke; where it did not, it was silent — this asymmetry is significant. The legislature’s deliberate choice not to include an equivalent own-initiative provision in Titles III and IV supports the inference that it did not intend to regulate own-initiative admissions of ARTs and EMTs in the same way.

The Commission’s Q&A attempts to bridge this gap by characterising own-initiative admissions as falling within Articles 16(1) and 48(1)’s prohibition on “seeking admission to trading.” But this characterisation conflicts with the legislature’s own terminology. MiCA consistently distinguishes between “seeking admission to trading” — an act by a person applying for a listing — and “admission to trading on the initiative of the operator of the trading platform” — an act by the exchange itself. These are treated as different concepts throughout MiCA’s text. The Commission’s Q&A essentially asks readers to treat them as synonymous, without any textual basis for doing so.

The BCAS opinion develops this argument at pages 20-21 with reference to the specific wording of Article 5(2), Recital 32, and the broader structural architecture of MiCA’s Title II versus Titles III and IV. The argument is coherent and textually grounded. It is not a fringe position — it represents a legitimate and defensible reading of the Regulation’s text.

The counter-argument, as articulated by Andrea Pantaleo and others in the expert discourse captured in practitioner forums, is that the categorical language of Article 48(1) — “a person shall not make an offer to the public or seek the admission to trading of an e-money token, within the Union, unless that person is the issuer” and meets the authorisation requirements — is broad enough to capture any act that results in an EMT being tradeable on an EU platform, regardless of who initiates it. This reading prioritises the protective purpose of Title IV over its precise textual architecture. It is not unreasonable, but it requires reading the Commission’s Q&A characterisation into the statutory text rather than reading it from the text itself.

7. Critique 3 — The Ultra Vires Application of EMD II to Extra-EU Issuers

The ESMA statement and Commission Q&A suggest that all issuers of EMTs must be authorised in accordance with the Electronic Money Directive II (Directive 2009/110/EC, EMD II). This suggestion, if taken to its logical conclusion, would mean that any person anywhere in the world who issues an EMT — even without offering it to the public in the Union or seeking any EU listing — must be authorised as an EMI or credit institution under EU law.

This reading is legally untenable, and the BCAS opinion correctly characterises it as a blatant ultra vires application of EU law — that is, extending legislation beyond the limits of the Union’s legislative competence.

The EMD II, like MiCA, is predicated on the Union’s competence to regulate activities conducted within the EU. Article 48(3) of MiCA makes the EMD II applicable to EMTs, but only in the context that Article 48(2) assimilates EMTs to electronic money — and the EMD II itself only prohibits the issuance of electronic money in the Union by non-authorised persons. An issuer located outside the Union, not conducting any offer to the public in the Union and not seeking any EU admission to trading, is not issuing electronic money “in the Union” — it is issuing a digital asset outside the Union that happens to be accessible to Union users through trading platforms.

Extending the EMD II’s authorisation requirement to extra-EU issuers who have no presence, no offer activity, and no listing-seeking activity in the Union would represent an extraordinary assertion of extraterritorial regulatory jurisdiction. EU law has no general basis for requiring non-EU entities conducting non-EU activities to comply with EU authorisation requirements. The principle of territoriality in EU regulation is foundational — it is what gives MiCA’s jurisdictional scope provisions meaning. Reading ESMA’s statement and the Commission Q&A as requiring all global EMT issuers to be EU-authorised would effectively give MiCA global applicability over every stablecoin issuer in the world, regardless of their EU nexus.

This critique does not mean that the EMD II has no role in the MiCA framework — Article 48(2) and (3) clearly integrate it for EMTs that are offered to the public or whose admission to trading is sought in the Union. The critique is specifically directed at extending that integration to issuers with no EU activity.

8. Critique 4 — The Non-Identifiable Issuer Carve-Out Under Recital 22

MiCA Recital 22 states that crypto-assets with non-identifiable issuers fall outside the scope of Titles III and IV. CASPs providing services in respect of such crypto-assets should still comply with their Title V obligations. This is an express legislative carve-out for decentralised protocols where no single person or entity exercises control over the issuance of the crypto-asset.

The ESMA statement’s instruction to delist all non-MiCA-authorised ARTs and EMTs does not adequately engage with the Recital 22 carve-out. If the Sky DAO — governed by approximately 101,784 governance token holders as of January 2025 — qualifies as a non-identifiable issuer, then DAI and USDS are outside the scope of Titles III and IV entirely. The ESMA statement would be directing trading platforms to delist tokens that the legislature has expressly placed outside the regulatory perimeter that the statement purports to enforce.

ESMA’s failure to address Recital 22 is a material gap in the statement’s legal reasoning. A complete analysis of the own-initiative listing question cannot ignore the non-identifiable issuer framework — it is part of MiCA’s architecture and directly affects the regulatory categorisation of the tokens most prominently affected by the statement’s directive.

Furthermore, ESMA’s statement effectively singles out non-identifiable issuers of ARTs and EMTs for treatment equivalent to that of non-authorised identifiable issuers, while Recital 22 expressly distinguishes between them. Non-identifiable issuers and their tokens are placed outside Titles III and IV, with CASPs simply required to comply with their Title V obligations. Treating tokens from non-identifiable issuers as “non-MiCA compliant” in the same sense as tokens from non-authorised identifiable issuers has no basis in the legislative text and arguably contradicts the express intent of Recital 22.

9. Critique 5 — Admission to Trading Is Explicitly Not an Offer to the Public

One of the clearest provisions in MiCA on this subject is Recital 28, which states that “the mere admission to trading or the publication of bid and offer prices should not, in and of itself, be regarded as an offer to the public of crypto-assets.” Recital 41 reinforces this by confirming that admission to trading and offers to the public are distinct regulatory categories.

This distinction is not incidental — it is structurally important to MiCA’s entire architecture. The regulation imposes different obligations on different actors depending on whether they are conducting an offer to the public, seeking admission to trading, operating a trading platform, or providing other crypto-asset services. These categories are designed to be distinct, and conflating them creates exactly the kind of incongruous result that Recital 28 is designed to prevent.

The Commission’s Q&A acknowledges Recital 28 indirectly when it states that the mere publication of bids and offers is not an offer to the public. But it then argues that the act of admitting an EMT to trading on the platform’s own initiative constitutes “seeking admission to trading” under Articles 16(1) and 48(1). This manoeuvre asks the reader to accept that an exchange’s own-initiative listing decision is simultaneously: (a) not an offer to the public per Recital 28, but (b) a form of seeking admission to trading per Articles 16(1) and 48(1).

This is a difficult conceptual position to sustain. “Seeking admission to trading” in MiCA’s architecture refers to an act by a person — the issuer or an authorised offeror — applying for their token to be admitted to a trading platform. It is an outward-directed solicitation by a token party toward an exchange. An exchange making an internal decision to list a token on its own platform is not “seeking” anything — it is unilaterally exercising its own operational discretion. The Commission’s characterisation requires stretching the word “seeking” well beyond its ordinary meaning and beyond the conceptual framework that MiCA’s text supports.

ESMA’s own statement partially acknowledges this when it uses the phrase “generally expected to prioritise restricting” rather than imposing a flat prohibition. This hedged language suggests that even ESMA recognises the textual case is not airtight — which is itself informative about the strength of the legal position underlying the statement.

10. Critique 6 — The Promotion and Advertising Boundary Is Where the Analysis Actually Lands

Having identified the weaknesses in ESMA’s broader argument, it is important to acknowledge the element of both publications that is analytically sound and represents a genuine regulatory risk for CASPs: the promotion and advertising threshold.

The Commission’s Q&A correctly identifies that CASPs providing exchange and other services in relation to non-MiCA-compliant ARTs and EMTs do not automatically constitute offers to the public — but they do so if “the relevant CASPs promote or advertise, as part of these services, an ART or EMT.” This is a defensible and textually grounded position. An active promotional campaign for USDT — featuring it as a recommended asset, running yield incentives specifically tied to it, or advertising its benefits in client communications — creates a meaningful argument that the CASP is itself conducting a communication presenting sufficient information to enable prospective holders to decide whether to acquire the token. This is much closer to the MiCA definition of an offer to the public than passive listing.

The implication for CASPs is clear and consistent across both the BCAS analysis and the Commission Q&A: passive listing is materially different from active promotion. A CASP that lists USDT as one of its many tradeable assets without giving it promotional prominence sits in a different regulatory position from one that runs a “USDT feature week” with zero-fee trading, homepage placement, and client email campaigns. The former is a defensible own-initiative listing posture; the latter risks being characterised as conducting an offer to the public, regardless of where you land on the own-initiative debate.

This is the most practically actionable element of the entire ESMA/Commission publication package — and it is also the element that most directly aligns with MiCA’s textual architecture. CASPs should ensure their marketing and product teams understand this distinction and that it is enforced in practice.

11. Where ESMA and the Commission Are on Stronger Ground

A rigorous analysis must acknowledge the arguments that support ESMA’s position, even where the overall conclusion of the BCAS opinion is more textually precise.

The purposive argument for ESMA’s position is genuine. MiCA was designed to create an orderly, authorisation-based framework for stablecoins in the EU market. The legislative purpose of Titles III and IV is to ensure that stablecoins available to EU retail investors meet minimum standards of reserve management, governance, and consumer protection. A reading of MiCA that allows the entire purpose of those Titles to be circumvented by the simple mechanism of exchanges listing tokens “on their own initiative” — rather than at the issuer’s request — does create a significant regulatory gap. This purposive concern is real, even if the textual case for ESMA’s position is weaker than its statement implies.

The Article 16(1) and Article 48(1) language is also genuinely broad. Article 48(1) states that a person “shall not make an offer to the public or seek the admission to trading of an e-money token, within the Union” unless the conditions are met. The text does not expressly exclude trading platforms from the category of “persons” who can “seek admission to trading.” A contextual reading that includes a trading platform’s own-initiative admission within the meaning of “seeking” — while textually strained — is not wholly without foundation, particularly if one reads “seek” as capturing any act that causes admission to trading to occur, regardless of who initiates it.

The BCAS opinion’s counter-argument — that the legislature deliberately distinguished between the two concepts — is the stronger textual position. But the existence of a genuine counter-argument is worth acknowledging, because it underscores that the matter is one of legitimate interpretive dispute rather than clear error by ESMA.

12. The Enforcement Spree Thesis: Will NCAs Act Regardless?

One of the most practically significant observations made in expert practitioner discussions is what might be called the enforcement spree thesis: that regardless of the legal merits of the ESMA position, NCAs across the EU face institutional incentives to take enforcement action against CASPs that have not delisted non-MiCA-compliant stablecoins.

The argument runs as follows. ESMA has publicly signalled its expectation that trading platforms will delist non-MiCA-compliant ARTs and EMTs. If NCAs are seen to be tolerating continued listings without taking any supervisory action, they risk being characterised as failing to enforce MiCA — a characterisation that could be used to support arguments for centralising supervisory authority at ESMA level, removing enforcement power from national regulators. In this reading, NCAs have a political incentive to demonstrate enforcement activity around the ESMA statement, not because they are legally required to follow it, but because failing to do so exposes them to institutional pressure from Brussels.

This thesis has observable support in the market data. The period following the ESMA statement has seen increased supervisory attention to stablecoin listings across multiple member states, even in jurisdictions whose NCAs have not publicly endorsed the ESMA position. Whether this reflects genuine legal conviction or institutional self-preservation is difficult to determine from outside the supervisory process — but its practical consequence for CASPs is the same either way.

The broader debate about centralising ESMA’s supervisory role over CASPs is ongoing in EU policy discussions. Some member states have opposed this move, precisely because it would remove national supervisory discretion. The enforcement spree dynamic, if it materialises as some practitioners predict, could itself become an argument in that policy debate — NCAs demonstrating enforcement activity to protect their supervisory turf.

For compliance officers, the practical implication of the enforcement spree thesis is straightforward: even if the BCAS legal position is correct as a matter of statutory interpretation, the risk of enforcement action by your home NCA is not merely a function of the law’s text. It is also a function of the institutional incentives operating on your NCA, and those incentives currently favour action over inaction.

13. The XBRL Taxonomy Pressure Point

A secondary but significant pressure point for non-MiCA-compliant stablecoin listings is the forthcoming ESMA XBRL taxonomy for MiCA whitepapers. Commission Implementing Regulation (EU) 2984 is expected to require that whitepapers for EMTs and ARTs comply with the ESMA XBRL taxonomy in order to be included in the ESMA register. CASPs should confirm the precise applicability date against the published implementing regulation, but market participants have been preparing for a late 2025 implementation.

Once the taxonomy is operative, the ESMA register will effectively function as a practical listing directory — tokens with taxonomy-compliant whitepapers will appear in the register; tokens without them will not. A CASP’s Article 76(1)(a) operating rules must include a provision stating that tokens whose whitepapers should have been published in compliance with MiCA but have not been are not to be admitted to trading. If the taxonomy becomes the de facto standard for “MiCA-compliant whitepaper,” then tokens whose issuers have not submitted taxonomy-compliant whitepapers — including DAI, USDS, and USDT under ESMA’s reading — would trigger the operating rules prohibition.

However, the BCAS analysis correctly identifies that the operating rules prohibition only applies in the “cases required by MiCA” — i.e., where an offer to the public or seeking of admission to trading has occurred. If neither has occurred, no whitepaper was required in the first place, and the operating rules prohibition does not engage. The XBRL taxonomy pressure point therefore reinforces the existing debate rather than resolving it: its practical effect depends entirely on how the underlying own-initiative listing question is resolved.

14. The Commission Centralisation Debate and Its Enforcement Implications

Running parallel to the stablecoin listing debate is a broader EU institutional discussion about whether ESMA should be given direct supervisory competence over the largest CASPs operating across multiple member states, rather than leaving supervision exclusively to home member state NCAs.

This debate is relevant to the ESMA statement in a specific way. If ESMA obtains direct supervisory authority over major CASPs, its public statements on stablecoin listings would carry materially different practical weight — not because they would be any more legally binding as formal instruments, but because ESMA would have the direct enforcement tools to act on its expressed expectations without relying on NCA intermediation.

Several practitioners have noted that this institutional dynamic creates perverse incentives in the current environment. NCAs that have been least aggressive in enforcing the ESMA statement — either because they are persuaded by the BCAS analysis or because they are commercially cautious about disadvantaging their domestic crypto industry — may find themselves most vulnerable to arguments that their supervisory passivity justifies transferring competence to ESMA. This creates pressure to enforce the ESMA statement not on its legal merits, but as a defensive institutional manoeuvre.

ComplyFactor’s ongoing tracking of EU regulatory developments — including our UK regulatory changes guide, MiCA regulation overview, and 6 AML trends analysis — covers these institutional developments as they evolve. CASPs should monitor the centralisation debate as a forward-looking variable in their regulatory risk assessments.

15. What the Market Divergence Tells Us About Regulatory Reality

The fragmented market response to the ESMA statement is itself instructive evidence about the statement’s legal standing and practical enforceability.

Bitpanda — one of the most prominent MiCA-authorised exchanges in Europe, headquartered in Vienna and supervised by the Austrian FMA — delisted USDT and other non-MiCA-compliant stablecoins in apparent response to the ESMA statement. This is the most visible example of direct compliance with ESMA’s expectation.

Revolut — operating across the EU with regulated entities in multiple member states including Lithuania — retained USDT on its payment and exchange app while removing it from Revolut X, its dedicated trading platform. This bifurcation is precisely what the legal analysis supports: the admission-to-trading framework applies to the trading platform service, not to the exchange service. Revolut’s approach suggests a legal team that engaged substantively with the distinction between service types rather than applying a blanket delisting across all products.

Multiple other exchanges across Germany, France, the Netherlands, and other major EU crypto markets maintained USDT listings into Q1 2025 and beyond, with their legal teams either concluding that the BCAS analysis supported continued listing or treating the matter as unresolved pending further regulatory clarity.

This divergence across exchanges in different member states — with different NCAs taking different approaches — is precisely what you would expect if the ESMA statement were not legally binding and if the underlying statutory question were genuinely contested. It is not what you would expect if the statement represented clear, binding law. The market divergence is, in this sense, a data point that itself supports the conclusion that the ESMA statement’s legal correctness is contestable.

For a broader view of how the divergent regulatory landscape is affecting CASPs and VASPs globally, including parallel developments in the UAE, UK, and Switzerland, ComplyFactor’s VASP compliance guide, UAE crypto regulation overview, and Switzerland AML audit guide provide useful comparative context.

16. Practical Implications for CASPs: Navigating Between Legal Argument and Regulatory Risk

Having set out both the legal critique of the ESMA statement and the genuine arguments in its favour, this section draws the analysis together into practical guidance for compliance officers navigating the decision in real time.

Step 1 — Establish your home NCA’s position. The single most important variable in your risk assessment is whether your home member state NCA has publicly aligned with the ESMA statement, remained silent, or indicated any departure from it. This requires monitoring your NCA’s publications, supervisory letters, and any bilateral communication with your compliance team. An NCA that has publicly endorsed ESMA’s position presents a fundamentally different enforcement risk profile from one that has been silent.

Step 2 — Obtain jurisdiction-specific legal advice. The BCAS opinion is a well-constructed legal argument, but it is a general analysis of MiCA’s text. It is not a legal opinion addressed to your specific entity, in your specific jurisdiction, under the supervisory posture of your specific NCA. Before making a board-level decision to maintain listings in reliance on the BCAS analysis, you need legal advice that accounts for your specific circumstances.

Step 3 — Document the legal risk analysis. Whatever decision you make — delist or maintain — it must be documented with a written legal risk assessment approved at board or senior management level. This documentation should set out the legal arguments on both sides, the weight you have assigned to ESMA’s statement given its non-binding character, the weight you have assigned to the BCAS analysis, and the specific risk mitigation measures you have put in place.

Step 4 — Eliminate promotional activity for non-MiCA-compliant tokens. This is the element of the ESMA/Commission analysis that is most textually defensible and presents the least legal uncertainty. Regardless of your position on the own-initiative listing question, active promotion or advertising of non-MiCA-compliant EMTs creates genuine offer-to-the-public risk. Audit your marketing and product presentation and ensure passive listing is clearly distinguished from promotional activity.

Step 5 — Implement robust Article 76 suitability and monitoring frameworks. The Title V obligations apply to your listings regardless of the interpretive dispute. A strong Article 76 compliance posture — documented suitability assessments, AML/CTF risk assessments, ongoing monitoring, and written operating rules — demonstrates to your NCA that your listing decisions are made with regulatory rigour. This does not eliminate enforcement risk, but it substantially improves your position in any supervisory dialogue.

Step 6 — Monitor the enforcement landscape on a rolling basis. This is not a static question. NCA enforcement actions, ESMA peer review findings, court or tribunal decisions, and legislative developments in the AMLR/AMLA transition will all affect the risk calculus over the coming months and years. A compliance framework that was appropriate in Q1 2025 may need revision by Q4 2025 depending on how the enforcement landscape evolves.

ComplyFactor’s AML advisory services, AML audit services, AML risk assessment calculator, and complete AML programme blueprint provide the structured framework for building and maintaining the compliance posture described in Steps 4 and 5. Our global MLRO services are available to CASPs that need senior compliance leadership on an outsourced basis while navigating these decisions.

17. Frequently Asked Questions

Q: Is ESMA’s January 2025 public statement legally binding on EU exchanges? A: No. ESMA public statements are supervisory communications — they express ESMA’s interpretation of applicable law and its expectations of market participants, but they do not constitute binding legal obligations equivalent to the MiCA Regulation itself, binding technical standards, or formal supervisory decisions. NCAs are not legally bound by ESMA public statements, though they face institutional incentives to align with them.

Q: Is the BCAS legal opinion a reliable basis for maintaining USDT or DAI listings? A: The BCAS opinion is a well-constructed and textually grounded legal argument. It is the most detailed published analysis supporting the permissibility of own-initiative EMT listings. However, it is a general analysis, not legal advice to any specific entity. A CASP wishing to rely on it should obtain its own jurisdiction-specific legal advice that accounts for its home NCA’s position and the specific facts of its business.

Q: Does ESMA have the power to compel NCAs to enforce its stablecoin statement? A: Not directly through the public statement itself. ESMA’s tools for compelling NCA action include the breach of Union law procedure under Article 17 of the ESMA Regulation — a formal, procedurally heavy mechanism. ESMA would be unlikely to invoke this procedure solely because an NCA has taken a more permissive approach to own-initiative stablecoin listings. Informal supervisory convergence pressure is more likely than formal compulsion.

Q: If the BCAS analysis is correct, why did Bitpanda delist USDT? A: Bitpanda’s decision was a commercial and regulatory risk management decision made in the context of its specific legal advice, its relationship with the Austrian FMA, and its assessment of the enforcement risk in its jurisdiction. It does not represent a concession that the BCAS analysis is wrong. It represents a judgment that the regulatory risk of maintaining listings — given the ESMA statement and FMA’s posture — outweighed the commercial benefit of retaining USDT pairs.

Q: What would resolve the legal uncertainty definitively? A: A definitive resolution requires one of: a binding ESMA regulatory technical standard or formal supervisory decision specifically addressing own-initiative listings; a binding NCA enforcement decision that is tested through administrative or judicial review, producing a precedent on the statutory interpretation question; or a Court of Justice of the European Union ruling on the correct interpretation of Articles 5(2), 16(1), and 48(1). None of these outcomes is imminent.

Q: Could the legislature amend MiCA to close the own-initiative listing gap? A: Yes, and this is probably the most likely long-term resolution. The Commission’s forthcoming Article 142 DeFi report and any resulting legislative proposal could address the own-initiative listing question directly, either by confirming ESMA’s interpretation through formal legislation or by creating a specific own-initiative listing framework for ARTs and EMTs analogous to Article 5(2) for other crypto-assets. Any such amendment would apply prospectively and would not retroactively validate or invalidate listing decisions made before its adoption.

This article is published for informational purposes and does not constitute legal advice. For MiCA compliance advisory, CASP AML programme development, fractional MLRO services, and regulatory risk assessments, contact ComplyFactor.

Related Articles:

• Can EU Exchanges Still List USDT, DAI and USDS Under MiCA? The Legal Debate Explained
• MiCA Admission to Trading: What Every CASP Compliance Officer Must Know Before Listing a Stablecoin
• MiCA Regulation Guide 2026: EU Crypto-Asset Framework Explained
• Ultimate Guide to VASP Compliance: Global AML/CTF/PF Standards
• Offshore VASPs: FATF’s 2026 oVASP Risk Report Explained
• UK Regulatory Changes 2026: Complete Compliance Guide for Crypto and Fintech
• UAE Crypto Regulation 2025: Complete Guide to VARA, ADGM, SCA, CBUAE
• 6 AML Trends in Regulatory Compliance Every Compliance Officer Needs to Follow
• Switzerland 2025 AML Audit and Independent Review Guide
• The Complete AML Program Blueprint: Design, Build and Implement